Seven Eight Capital, LP Fibrogen Inc Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$23.3 - $45.96 $390,391 - $770,059	-16,755 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$34.58 - $48.06 $854,126 - $1.19 Million	-24,700 Reduced 59.58%	16,755 $719,000
Q3 2019 Nov 14, 2019	BUY	$36.98 - $48.45 $1.53 Million - $2.01 Million	41,455 New	41,455 $1.53 Million
Q2 2019 Aug 12, 2019	SELL	$35.13 - $55.53 $189,877 - $300,139	-5,405 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $231,496 - $323,813	5,405 New	5,405 $294,000
Q1 2018 May 14, 2018	SELL	$45.35 - $61.65 $362,800 - $493,200	-8,000 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$41.95 - $60.1 $335,600 - $480,800	8,000	8,000 $379,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.